2020 The Year Of RAP, page-783

I agree with your comment yesterday@Red bar regarding cap raise.

We would almost certainly have had a cap raise in the 0.30's if management thought there was asignificant probability of failure. Have seen the mining/explorationjuniors pull the trigger as soon as spspikes many many times.

Remember, for FDA classification we need to demonstrate that the medical device is:
1) Safe...its a phone app fffs...I am sure with a general control of "Caution: Not for use as the basis for treatment without independent medical confirmation".
2) Effective...yep 73-77% PPA and 70-86% NPA (and better than 3 Drs could agree upon) from 1,470 patients at 3 top hospitals in the USA.

Worth remembering what can happen when this news finally hits...from some of the Aussie companies that got FDA approval in 2018/2019:

LBT: intraday high +250%
CUV: intraday high +60%
AVH: intraday high +148%

Using above examples and a RAP closing price pre-announcement of say 0.25; then with FDA approval we may see:

Base case (+60%) = +0.40
Average case (154%) = +0.60
Upside case (+250%) = +0.87

Peace out!